WAT

In the past six months, Waters Corp. (WAT) stock has seen significant activity. As of September 29, 2026, the share price was $443.48, marking a 47.92% increase from $299.81 on September 30, 2025. The early 2026 merger with Becton Dickinson's life science and diagnostics business was positively received by investors, expanding Waters' exposure to diagnostics and life-science research. Waters reported strong financial results in Q1 2026, with total revenue of $1.267 billion, exceeding expectations and leading to an increased full-year 2026 organic constant currency revenue growth guidance of 6.5%–8.0%. Q2 2026 also saw robust performance, with $3.05 EPS (beating estimates of $3.01) and revenue of $1.65 billion (surpassing analyst estimates of $1.62 billion), further raising full-year guidance. The company's shares reached a new 52-week high, trading as high as $454.54 in early October 2026. Analysts have maintained a broadly optimistic outlook, with a consensus 'Moderate Buy' rating and an average target price of $437.10, with several firms like Royal Bank of Canada, Citigroup, Barclays, and Goldman Sachs raising their price targets in August and September 2026. Waters demonstrated relative resilience within the Medical Diagnostics & Research industry despite broader market pullbacks.